MedTrace Logo

Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2

NCT05715944 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10888

Last updated 2023-02-08

No results posted yet for this study

Summary

The AstraZeneca Study is a single-arm, open-label, interventional, Phase 3b study to determine the incidence of laboratory-confirmed COVID-19 hospitalizations, disease severity, and deaths and attributable adverse events (AEs) in participants in Botswana given 1 to 2 injections of AZD1222 eight to twelve weeks apart as primary series and/or 1 injection as booster dose. Length of follow-up will be 6 to 12 months, depending upon at which dose a participant is enrolled.

Conditions

Interventions

DRUG

AZD 1222

Vaccine

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Botswana Ministry of Health

    collaborator OTHER_GOV

  • Botswana Harvard AIDS Institute Partnership

    lead OTHER

Principal Investigators

  • Joseph M Makhema, FRCP · Botswana Harvard AIDS Institute Partnership

  • Tendani Gaolathe, M.,Med · University of Botswana, Botswana Harvard Health Partnership

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-15
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • Botswana

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05715944 on ClinicalTrials.gov